Ben Fangman, MD

Articles by Ben Fangman, MD

Circulating Tumor DNA as a Marker of Minimal Residual Disease

ByBen Fangman, MD,Kanwal Raghav, MD,Scott Kopetz, MD, PhD

October 13th 2022

Ben Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual disease in colorectal cancer.

Latest Updated Articles

Circulating Tumor DNA as a Marker of Minimal Residual Disease
October 13th 2022

Trending on CancerNetwork

FDA Approves Ruxolitinib Tablets for Hematologic Malignancies

Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer

Precision Medicine and the “Slow Death” of Transplant in Lymphoma

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study